Taloside Inhibitors of Galectin-1 and Galectin-3

Chemical Biology and Drug Design

Volumn 79, Issue 3, 2012, Pages 339-346

  Collins, Patrick M ^a   Öberg, Christopher T ^b   Leffler, Hakon ^b   Nilsson, Ulf J ^b   Blanchard, Helen ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Carbohydrates; Galectin; Inhibitor design; Protein X ray crystal structures; Talosides

Indexed keywords

GALACTOSE; GALECTIN 1; GALECTIN 3; INHIBITOR PROTEIN; METHYL 2 O ACETYL 3 O TOLUOYL BETA DEXTRO TALOPYRANOSIDE; METHYL 3 DEOXY 2 O TOLUOYL 3 N TOLUOYL BETA DEXTRO TALOPYRANOSIDE; TALOSIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; X RAY CRYSTALLOGRAPHY;

BENZAMIDES; BENZOATES; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; GALECTIN 1; GALECTIN 3; GLYCOSIDES; HUMANS; PROTEIN STRUCTURE, TERTIARY;

EID: 84856030573     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01283.x     Document Type: Article

References (35)

1. Vasta G.R. (2009) Roles of galectins in infection. Nat Rev Microbiol;7:424-438.
2. Liu F.T. (2000) Galectins: a new family of regulators of inflammation. Clin Immunol;97:79-88.
3. Liu F.T., Rabinovich G.A. (2005) Galectins as modulators of tumour progression. Nat Rev Cancer;5:29-41.
4. Delaine T., Cumpstey I., Ingrassia L., Le Mercier M., Okechukwu P., Leffler H., Kiss R., Nilsson U.J. (2008) Galectin-inhibitory thiodigalactoside ester derivatives have antimigratory effects in cultured lung and prostate cancer cells. J Med Chem;51:8109-8114.
5. MacKinnon A.C., Farnworth S.L., Hodkinson P.S., Henderson N.C., Atkinson K.M., Leffler H., Nilsson U.J., Haslett C., Forbes S.J., Sethi T. (2008) Regulation of alternative macrophage activation by galectin-3. J Immunol;180:2650-2658.
6. Stannard K.A., Collins P.M., Ito K., Sullivan E.M., Scott S.A., Gabutero E., Grice I.D., Low P., Nilsson U.J., Leffler H., Blanchard H., Ralph S.J. (2010) Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model. Cancer Lett;299:95-110.
7. Barondes S.H., Cooper D.N., Gitt M.A., Leffler H. (1994) Galectins. Structure and function of a large family of animal lectins. J Biol Chem;269:20807-20810.
8. Grigorian A., Torossian S., Demetriou M. (2009) T-cell growth, cell surface organisation, and galectin-glycoprotein lattice. Immunol Rev;230:232-246.
9. Hsu D.K., Liu F.T. (2004) Regulation of cellular homeostasis by galectins. Glycoconj J;19:507-515.
10. Liu F.T., Patterson R.J., Wang J.L. (2002) Intracellular functions of galectins. Biochim Biophys Acta;1572:263-273.
11. Yang R.Y., Liu F.T. (2003) Galectins in cell growth and apoptosis. Cell Mol Life Sci;60:267-276.
12. Nesmelova I.V., Dings R.P.M., Mayo K.H. (2008) Understanding Galectin Structure-Function Relationships to Design Effective Antagonists. In: Klyosov A.A., Witczak Z.J., Platt D., editors. Galectins. Hoboken: John Wiley & Sons, Inc.; p. 33-69.
13. Öberg C.T., Blanchard H., Leffler H., Nilsson U.J. (2008) Protein subtype-targeting through ligand epimerization: talose-selectivity of galectin-4 and galectin-8. Bioorg Med Chem Lett;18:3691-3694.
14. Cumpstey I., Sundin A., Leffler H., Nilsson U.J. (2005) C2-symmetrical thiodigalactoside bis-benzamido derivatives as high-affinity inhibitors of galectin-3: efficient lectin inhibition through double arginine-arene interactions. Angew Chem Int Ed Engl;44:5110-5112.
15. Sorme P., Qian Y., Nyholm P.G., Leffler H., Nilsson U.J. (2002) Low micromolar inhibitors of galectin-3 based 3′-derivatization of N-acetyllactosamine. Chembiochem;3:183-189.
16. Sorme P., Arnoux O.P., Kahl-Knutsson B., Leffler H., Rini J.M., Nilsson U.J. (2005) Structural and thermodynamic studies on cation-Pi interactions in lectin-ligand complexes: high-affinity galectin-3 inhibitors through fine-tuning of an arginine-arene interaction. J Am Chem Soc;127:1737-1743.
17. Öberg C.T., Leffler H., Nilsson U.J. (2008) Arginine binding motifs: design and synthesis of galactose-derived arginine tweezers as galectin-3 inhibitors. J Med Chem;51:2297-2301.
18. Salameh B.A., Cumpstey I., Sundin A., Leffler H., Nilsson U.J. (2010) 1H-1, 2, 3-trazol-1-yl thiodigalactoside derivatives as high affinity galectin-3 inhibitors. Bioorg Med Chem;18(14):5367-5378.
19. Seetharaman J., Kanigsberg A., Slaaby R., Leffler H., Barondes S.H., Rini J.M. (1998) X-ray crystal structure of the human galectin-3 carbohydrate recognition domain at 2.1-A resolution. J Biol Chem;273:13047-13052.
20. Lopez-Lucendo M.F., Solis D., Andre S., Hirabayashi J., Kasai K., Kaltner H., Gabius H.J., Romero A. (2004) Growth-regulatory human galectin-1: crystallographic characterisation of the structural changes induced by single-site mutations and their impact on the thermodynamics of ligand binding. J Mol Biol;343:957-970.
21. Scott S.A., Scott K., Blanchard H. (2007) Crystallisation and preliminary crystallographic analysis of recombinant human galectin-1. Acta Crystallogr Sect F Struct Biol Cryst Commun;63:967-971.
22. Collins P.M., Hidari K.I.P.J., Blanchard H. (2007) Slow diffusion of lactose out of galectin-3 crystals monitored by X-ray crystallography: possible implications for ligand-exchange protocols. Acta Crystallogr D Biol Crystallogr;63:415-419.
23. Öberg C.T., Noresson A.-L., Leffler H., Nilsson U.J. (2011) Synthesis of 3-amido-3-deoxy-β-d-talopyranosides: all-cis-substituted pyranosides as lectin inhibitors. Tetrahedron;67:9164-9172.
24. Evans P. (2006) Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr;62:72-82.
25. Murshudov G.N., Vagin A.A., Dodson E.J. (1997) Refinement of macromolecular structures by the maximum-likelihood methods. Acta Crystallogr D Biol Crystallogr;53:240-255.
26. Collaborative Computational Project (1994) Collaborative Computational Project. Acta Crystallogr D Biol Crystallogr; 50:760-763.
27. Emsley P., Lohkamp B., Scott W.G., Cowtan K. (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr;66:486-501.
28. Potterton L., McNicholas S., Krissinel E., Gruber J., Cowtan K., Emsley P., Murshudov G.N., Cohen S., Perrakis A., Noble M. (2004) Developments in the CCP4 molecular-graphics project. Acta Crystallogr D Biol Crystallogr;60:2288-2294.
29. Diehl Engstrom C.O., Delaine T., Hakansson M., Genheden S., Modig K., Ryde U., Nilsson U.J., Akke M. (2010) Protein flexibility and conformational entropy in ligand design targeting the carbohydrate recognition domain of galectin-3. J Am Chem Soc;132:14577-14589.
30. Nishi N., Abe A., Iwaki J., Yoshida H., Itoh A., Shoji H., Kamitori S., Hirabayashi J., Nakamura T. (2008) Functional and structural basis of a cysteine-less mutant as a long-lasting substitute for galectin-1. Glycobiology;18:1065-1073.
31. Abbott W.M., Feizi T. (1991) Antigenic cross-reaction between beta-galactoside binding lectin and myelin basic protein. J Biol Chem;266:5552-5557.
32. Cauet E., Rooman M., Wintjens R., Lievin J., Biot C. (2005) Histidine-aromatic interactions in proteins and protein-ligand complexes: Quantum chemical study of X-ray and model structures. Journal of Chemical Theory and Computation;1:472-483.
33. Hotta K., Funahashi T., Matsukawa Y., Takahashi M., Nishizawa H., Kishida K., Matsuda M., Kuriyama H., Kihara S., Nakamura T., Tochino Y., Bodkin N.L., Hansen B.C., Matsuzawa Y. (2001) Galectin-12, an adipose-expressed galectin-like molecule processing apoptosis-inducing activity. J Biol Chem;276:34089-34097.
34. Cooper D.N. (2002) Galectinomics: finding themes in complexity. Biochim Biophys Acta;1572:209-231.
35. Vaupel P., Kallinowski F., Okunieff P. (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumours: a review. Cancer Res;49:6449-6465.